European technology investor Amadeus Capital Partners has joined Montezemolo & Partners as an investor in Bellco. The business is a developer of equipment for haemo-dialysis used in kidney disease and is based in Mirandola, Italy.
European technology investor Amadeus Capital Partners has joined Montezemolo & Partners as an investor in Bellco, one of Europe’s leading and most innovative developers of equipment for haemo-dialysis used in kidney disease.
Bellco is based in Mirandola, Italy, in one of the largest medical technology clusters in the world that is also a centre of excellence for renal disease treatment and research. With plants in Mirandola and Toulouse, France, Bellco specialises in sophisticated products for extra-corporeal blood filtration. The company employs some 370 people at its two plants and at subsidiary operations in Spain, Belgium, Sweden and Canada and in 2012 generated over 100 million euros’ revenue and EBITDA approaching 15 million euros.
Building on a long tradition of technological innovation in haemo-dialysis, with “the right therapy” at its core, Bellco last year introduced new dialysers for both chronic and acute renal failure and launched a new generation of patented dialysers to treat sepsis and acute lung injury in intensive care units, as well as the first dialysis system for new-born babies.
Amadeus Partner, Andrea Traversone, said: “This is a highly innovative technology company with a long track record and an enviable reputation for reliability. We are delighted to join Montezemolo, whom we already know well and respect as a leading private equity and growth investor, in taking Bellco to the next stage of its development. Bellco’s products have the potential significantly to improve chronic haemo-dialysis worldwide and to revolutionise the acute dialysis sector with unique, patented therapies for life-threatening conditions.”
The underlying market drivers for renal therapies include growing elderly populations, increased incidence of early stage renal disease, largely due to diabetes and hypertension, and a shortage of kidney donors for transplantation.
Montezemolo invited Amadeus to join as a co-investor in Bellco on the basis of Amadeus’ experience of building successful medical technology companies, including Solexa and Optos. Montezemolo and Amadeus are co-investors in the worldwide market leader in insurance telematics, Octo Telematics.
Advisers on Amadeus’ investment were McDermott, Will & Emery, Milan.
For further information, please contact:
Chantal Ligertwood, PR for Amadeus, 07976 229 210
Amadeus Capital Partners is one of Europe’s leading technology investors. Since its inception in 1997, the firm has raised over £500m for investment and backed more than 85 companies in communications and networking hardware and software, cleantech, medtech, computer hardware and software, media, and e-commerce. Major businesses built by Amadeus include CSR plc (LSE:CSR), the leading producer of single chip bluetooth radios for short range connections, Solexa Ltd, the developer of next generation genetic analysis systems, merged into Illumina, Inc. (ILMN) to create the world-leader in gene-sequencing technology and Transmode, a networking solutions business, which had an over-subscribed IPO on NASDAQ OMX Stockholm in 2011.